Steven Chu, Stanford

Steven Chu is the William R. Kenan, Jr., Professor of Physics and Professor of Molecular & Cellular Physiology in the Medical School at Stanford University. He has published 260 papers in atomic and polymer physics, biophysics, biology, biomedicine, batteries, and holds 10 patents.

Dr. Chu was the 12th U.S. Secretary of Energy from January 2009 until the end of April 2013. As the first scientist to hold a Cabinet position and the longest serving Energy Secretary, he recruited outstanding scientists and engineers into the Department of Energy. He began several initiatives including ARPA-E (Advanced Research Projects Agency – Energy), the Energy Innovation Hubs, the U.S. – China Clean Energy Research Centers (CERC), and was tasked by President Obama to assist BP in stopping the Deepwater Horizon oil leak. Prior to his cabinet post, he was director of the Lawrence Berkeley National Laboratory and Professor of Physics and Molecular and Cell Biology at UC Berkeley. Previously he was the Theodore and Francis Geballe Professor of Physics and Applied Physics at Stanford University, and head of the Quantum Electronics Research Department at AT&T Bell Laboratories.

Dr. Chu has numerous awards including the 1997 Nobel Prize in Physics for the laser cooling and atom trapping, shared with Claude Cohen-Tannoudji and William Phillips. He holds 26 honorary degrees and is a member of the National Academy of Sciences, the American Philosophical Society, the American Academy of Arts and Sciences, the Academia Sinica, and is a foreign member of the Royal Society, the Royal Academy of Engineering, the Chinese Academy of Sciences, and the Korean Academy of Sciences and Technology.

Chancellor Sam Hawgood, UC San Francisco

Sam Hawgood, MBBS, is currently the Chancellor and holds the Arthur and Toni Rembe Rock Distinguished Professor appointment at UCSF.

Hawgood graduated with First Class Honors from the University of Queensland in Australia in 1975. After graduation, he trained in Australia in pediatrics with a sub-specialty interest in neonatology. Hawgood moved to UCSF in 1982 to work with William Tooley, MD, and John Clements, MD, pioneers in the discovery and therapeutic uses of pulmonary surfactant in premature babies.

Pulmonary surfactant keeps the lungs inflated and a developmental deficiency of surfactant is the major cause of the respiratory distress syndrome of the newborn (RDS). Hawgood’s interest in the biology of surfactant grew from clinical experience in neonatology where RDS is a major cause of neonatal death. He moved to UCSF in 1982 as a research fellow with Clements, the scientist that discovered surfactant in the late 1950’s. Hawgood started his own laboratory, focused on the proteins associated with surfactant, in 1984. A multi-disciplinary Program Project Grant from the National Heart, Lung and Blood Institute has supported his work since 1984. His scientific contributions over the last 25 years have been recognized by numerous invitations to present in national and international forums and continuous funding from the National Institutes of Health.

Hawgood has maintained an active presence in clinical medicine, serving as Division Chief of Neonatology at UCSF from 1994 to 2006. He has been an Associate Director of the CVRI since 1997, and was Chair of Pediatrics and Physician-in-Chief of the UCSF Children’s Hospital from 2003 to 2009. He is also currently President of the UCSF Medical Group, the faculty plan representing more than 1,000 physicians at UCSF.

In service to professional organizations Hawgood served on the Council of the Society for Pediatric Research for seven years between 1992 and 2000 and was President of the Society in 1999. He chaired the Program Committee for the Pediatric Academic Societies from 1998-2000 and in 2005 received the Distinguished Service Award from the Society for Pediatric Research. He was a Trustee and Secretary-Treasurer of the International Pediatric Research Society from 2003 to 2009. Hawgood has served on study sections for the NIH and is currently a member of the Program Project Parent Committee of the National Heart, Lung, and Blood Institute. In addition, Hawgood was recently elected to the Institute of Medicine (IOM), part of the National Academy of Sciences.

Bill Rutter, Synergenics

Bill Rutter is Chairman and Founder of Synergenics, LLC, which owns and controls a portfolio of Biotechnology companies at various stages of development.

In his academic career, Bill joined UCSF as head of the newly formed department of Biochemistry and Biophysics in 1968, and played a key role in developing UCSF into a major scientific institution.  In research, he is particularly known for the discovery of the enzymes involved in the expression of DNA (RNA polymerases); the first cloning of the insulin gene; the cloning of Hepatitis B virus (HBV), and formation of a Hepatitis B virus-like particle which provided the basis for a safe and protective vaccine.  

With two colleagues, Bill founded Chiron in 1981, a pioneering Biotech firm that developed (with Merck), the first recombinant vaccine (against HBV),  a process for manufacturing insulin from yeast (Novo-Nordisk),  Chiron alsowas the first to clone theAIDS (HIV) virus, and also the discovery, cloning and sequencing of the Hepatitis C (HCV)virus,  and developed quantitative diagnostic tests for the HIV, HBV, and HCV viruses, thus providing the means for eliminating blood contaminated with these viruses. This was a major contribution to public health worldwide.  Chironalso developed and promulgated the concept of"viral load"  as the basis for determining disease status, and also the basis for developing and evaluating antivirals, and other treatment protocols for these and other diseases. Ciba-Geigy, a major pharmaceutical company acquired 49% interest in Chiron in 1996, in exchange for their Diagnostic business (thus making Chiron a major Diagnostic company), half of theChiron-CibaGeigy vaccine business (thus making Chiron a major vaccine manufacturer), and substantial cash.  Later Ciba-Geigy merged with Sandoz to form Novartis. Bill resigned from the chairmanship of Chiron in 1999, and the Chiron Board in 2003.   Novartis purchased the remainder of Chiron in 2006.

Prior to Chiron, Bill was a consultant to Abbott Laboratories for ~ 20 years, and a member of the Amgen Scientific advisory board.   Bill’s board memberships includeNovartis 1995-1999, Sangamo Biosciences (1999-2005), Cytokinetics (1999-2005), Nugen (2002-2005), Oscient pharmaceuticals (1999-2005), Epitomics (2003-2012), Eureka Genomics (2012-present), Apexigen (2012-present), Boston Biomedical Institute (2012-present) and One Globe, and Cellworks (2013-present).  

He is a member of The National Academy of Sciences and the American Academy of Arts and Sciences, and has received numerous awards for his contributions to science and the biotechnology industry.


Richard Scheller, 23andMe

Richard H. Scheller joined 23andMe in April of 2015 as chief scientific officer and head of therapeutic development. He is responsible for translating genetic information into the discovery and development of new therapies for both common and rare diseases.

Prior to joining 23andMe, Scheller worked at Genentech, a member of the Roche Group. Scheller was responsible for overseeing the strategy for research, drug discovery, business development, and early development activities. He joined Genentech in 2001 as senior vice president of research and was promoted to executive vice president of research in 2003. In 2008, he was named chief scientific officer. Following the company’s merger with the Roche Group in 2009, Scheller was promoted to executive vice president and head of Genentech research and early development, and joined the Roche enlarged corporate executive committee. Scheller served as chairman of the Genentech Foundation’s board of directors.

Scheller received his bachelor of science in biochemistry in 1975 from the University of Wisconsin–Madison and his doctorate in chemistry in 1980 from the California Institute of Technology. After postdoctoral research fellowships at Caltech and the Columbia University College of Physicians and Surgeons, Scheller was hired as an assistant professor at Stanford University in 1982. In 1993, he was named a professor of molecular and cellular physiology and biological sciences, and in 1994 as an investigator with the Howard Hughes Medical Institute at Stanford University Medical Center. He has been an adjunct professor at UC San Francisco since 2004. Scheller's research elucidating the molecular mechanisms governing neurotransmitter release earned him the 2013 Albert Lasker Basic Medical Research Award, the 2010 Kavli Prize in Neuroscience, and the 1997 US National Academy of Sciences Award in Molecular Biology, among other honors. In 2014, he received a Distinguished Alumni Award from Caltech.

He is a fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences, and the National Academy of Medicine. He has served on numerous advisory boards, including the National Advisory Mental Health Council of the National Institutes of Health. In 2014, he was named a trustee of Caltech.